Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (311-320 of 387) with videos related to

Pageof 39
Sort By:
Journal of Viral Hepatitis|August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registryZobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Gastroenterologia Y Hepatologia|December 30, 2022
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapyJoan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, et al.
The New England Journal of Medicine|December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BPatrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology|October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis BE Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Human Vaccines & Immunotherapeutics|December 11, 2025
The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birthPierre Van Damme, Greet Hendrickx, Sakshi Jindal, et al.
Pageof 39

Showing results (311-320 of 387) with videos related to

Sort By:
Pageof 39
Journal of Viral Hepatitis|August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registryZobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Gastroenterologia Y Hepatologia|December 30, 2022
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapyJoan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, et al.
The New England Journal of Medicine|December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BPatrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology|October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis BE Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Human Vaccines & Immunotherapeutics|December 11, 2025
The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birthPierre Van Damme, Greet Hendrickx, Sakshi Jindal, et al.
Pageof 39